The rationale for our CSO conversion is listed in this onyx thread. Please be safe and prepared for more changes that Amgen is not telling us about in the new year.
http://ift.tt/14dcn2n
"Team Onyx who ever you are. The reason TH is being so nice to you and why you have preferential treatment is because TH pushed hard for your acquisition and quite frankly overpaid for Onyx. You aren't a bad buy, but still haven't proven to be worth the $10B since that was based off a forecast of generating at least $2B a year. TH knows that he will look bad if you can't deliver so he is willing to give you far more resources in terms of budget and headcount for you to make those revenue numbers. Noticed I said revenue. While other legacy Amgen business units will be judge of profitability, you get the pass on that as long as you hit top line numbers for now. Much like how VB has stripped other BUs of resources for CV, you get the same benefit. This is why the OBU and INBU are being downsized because both CV and Onyx are considered growth products."
"So basically political battles between new hires from newly formed BU (CV/Onyx) vs. legacy Amgen leadership in established business units that TH has no respect for is why INBU and OBU are targets for CSO conversion in 2015?"
"Unfortunately yes. Until TH leaves (word is he would for a top Biopharma CEO job), Onyx will likely be given preferential treatment until then."
http://ift.tt/14dcn2n
"Team Onyx who ever you are. The reason TH is being so nice to you and why you have preferential treatment is because TH pushed hard for your acquisition and quite frankly overpaid for Onyx. You aren't a bad buy, but still haven't proven to be worth the $10B since that was based off a forecast of generating at least $2B a year. TH knows that he will look bad if you can't deliver so he is willing to give you far more resources in terms of budget and headcount for you to make those revenue numbers. Noticed I said revenue. While other legacy Amgen business units will be judge of profitability, you get the pass on that as long as you hit top line numbers for now. Much like how VB has stripped other BUs of resources for CV, you get the same benefit. This is why the OBU and INBU are being downsized because both CV and Onyx are considered growth products."
"So basically political battles between new hires from newly formed BU (CV/Onyx) vs. legacy Amgen leadership in established business units that TH has no respect for is why INBU and OBU are targets for CSO conversion in 2015?"
"Unfortunately yes. Until TH leaves (word is he would for a top Biopharma CEO job), Onyx will likely be given preferential treatment until then."
To my fellow Amgen reps
Aucun commentaire:
Enregistrer un commentaire